Mohammad Hamza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammad Hamza has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Chadi Alraies
Detroit Medical Center Detroit Michigan USA
22 shared publications - Yasar Sattar
Department of Cardiology West Virginia University Morgantown West Virginia USA
10 shared publications - Amro Taha
Division of Cardiology, West Virginia University, Morgantown, WV 26506, USA
6 shared publications - Jawad Basit
Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan
6 shared publications Jawad Basit
5 shared publicationsPrakash Upreti
Sands Constellation Heart Institute, Rochester Regional Health, Rochester, NY, USA
5 shared publications
Latest Publications
- 15 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (6) , 2046-2058
Clinical Outcomes of Sodium Glucose Cotransporter‐2 Inhibitors in Patients Undergoing Mitral Transcatheter Edge‐to‐Edge Repair
Introduction: Adverse cardiovascular outcomes remain common among patients undergoing mitral transcatheter edge‐to‐edge repair (M‐TEER). Despite growing evidence supporting the cardiovascular benefits of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), large‐scale clinical data evaluating their efficacy in this specific population are limited. We aimed to assess cardiovascular outcomes associated with SGLT2i use compared with standard care using a large global research network database. Methods: A retrospective cohort study was conducted using de‐identified patient data from the TriNetX Global Research Network. Adult patients (≥ 18 years) undergoing M‐TEER were included and stratified into SGLT2i and usual care cohorts according to documented SGLT2i exposure before the index M‐TEER procedure. Propensity score matching (PSM) was performed to balance baseline characteristics between groups. Cox proportional hazards models were used to evaluate efficacy and safety outcomes at 6 months and 1‐year follow‐up. Results: A total of 6793 patients undergoing M‐TEER were identified, of whom 2192 received SGLT2i therapy. After PSM, 1407 patients remained in each cohort. At 6 months, the primary composite outcome (stroke, all‐cause mortality, and acute heart failure) showed no significant difference between groups (HR 0.90, p = 0.508). However, significant reductions were observed in all‐cause mortality (HR 0.74, p = 0.012) and all‐cause hospitalizations (HR 0.82, p < 0.001). At 1 year, the primary composite outcome remained nonsignificant (HR 0.87, p = 0.244), while reductions in all‐cause mortality (HR 0.76, p = 0.004) and all‐cause hospitalizations (HR 0.83, p < 0.001) persisted. Conclusion: Among patients undergoing M‐TEER, baseline SGLT2i use was associated with lower all‐cause mortality and hospitalization in this observational cohort.
- 15 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (6) , 2046-2058
Clinical Outcomes of Sodium Glucose Cotransporter‐2 Inhibitors in Patients Undergoing Mitral Transcatheter Edge‐to‐Edge Repair
Introduction: Adverse cardiovascular outcomes remain common among patients undergoing mitral transcatheter edge‐to‐edge repair (M‐TEER). Despite growing evidence supporting the cardiovascular benefits of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), large‐scale clinical data evaluating their efficacy in this specific population are limited. We aimed to assess cardiovascular outcomes associated with SGLT2i use compared with standard care using a large global research network database. Methods: A retrospective cohort study was conducted using de‐identified patient data from the TriNetX Global Research Network. Adult patients (≥ 18 years) undergoing M‐TEER were included and stratified into SGLT2i and usual care cohorts according to documented SGLT2i exposure before the index M‐TEER procedure. Propensity score matching (PSM) was performed to balance baseline characteristics between groups. Cox proportional hazards models were used to evaluate efficacy and safety outcomes at 6 months and 1‐year follow‐up. Results: A total of 6793 patients undergoing M‐TEER were identified, of whom 2192 received SGLT2i therapy. After PSM, 1407 patients remained in each cohort. At 6 months, the primary composite outcome (stroke, all‐cause mortality, and acute heart failure) showed no significant difference between groups (HR 0.90, p = 0.508). However, significant reductions were observed in all‐cause mortality (HR 0.74, p = 0.012) and all‐cause hospitalizations (HR 0.82, p < 0.001). At 1 year, the primary composite outcome remained nonsignificant (HR 0.87, p = 0.244), while reductions in all‐cause mortality (HR 0.76, p = 0.004) and all‐cause hospitalizations (HR 0.83, p < 0.001) persisted. Conclusion: Among patients undergoing M‐TEER, baseline SGLT2i use was associated with lower all‐cause mortality and hospitalization in this observational cohort.
- Open Access
- 9 July 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science – Atherosclerotic Diseases
- Vol. 11 (1) , 159-166
Colchicine’s promise in post-ablation atrial fibrillation: a meta-analysis
Introduction: Catheter ablation for restoration of sinus rhythm is limited by the high rates of arrhythmia due to inflammation caused by the procedure. Colchicine, a microtubule polymerisation inhibitor, reduces inflammation and may decrease atrial arrhythmia recurrence. We conducted a meta-analysis of RCTs and observational studies to assess the efficacy of colchicine in reducing atrial fibrillation (A fib) recurrence and pericarditis. Methods: We identified seven studies through the systematic search of the PubMed, Embase, and Cochrane databases from inception to March 2024. Eligible articles had to be RCTs or observational studies comparing the effectiveness of colchicine with placebo in patients who underwent catheter ablation. Outcomes included A fib recurrence, atrial tachycardia, need to perform cardioversion or re-ablation, gastrointestinal (GI) adverse effects, pericarditis, and repeat hospitalisation. A random effects model was used to analyse binary outcomes, and the Mantel-Haenszel method was used to calculate the odds ratio with a 95% confidence interval. Results: Data from 2165 patients were analysed. Colchicine reduced A fib OR = 0.61 (p = 0.001), pericarditis OR = 0.54 (p = 0.07), and the need for re-ablation OR = 0.53 (p = 0.36). However, it increased GI adverse effects OR = 3.15 (p = 0.008). There was no statistical difference in the need for cardioversion, repeat hospitalisation, and atrial tachycardia between the two groups. Conclusions: Although colchicine significantly reduced the recurrence of A fib, further investigation is needed for a comprehensive understanding of the efficacy of colchicine in patients with catheter ablation.
- 9 July 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science – Atherosclerotic Diseases
- Vol. 11 (1) , 159-166
Open AccessColchicine’s promise in post-ablation atrial fibrillation: a meta-analysis
Introduction: Catheter ablation for restoration of sinus rhythm is limited by the high rates of arrhythmia due to inflammation caused by the procedure. Colchicine, a microtubule polymerisation inhibitor, reduces inflammation and may decrease atrial arrhythmia recurrence. We conducted a meta-analysis of RCTs and observational studies to assess the efficacy of colchicine in reducing atrial fibrillation (A fib) recurrence and pericarditis. Methods: We identified seven studies through the systematic search of the PubMed, Embase, and Cochrane databases from inception to March 2024. Eligible articles had to be RCTs or observational studies comparing the effectiveness of colchicine with placebo in patients who underwent catheter ablation. Outcomes included A fib recurrence, atrial tachycardia, need to perform cardioversion or re-ablation, gastrointestinal (GI) adverse effects, pericarditis, and repeat hospitalisation. A random effects model was used to analyse binary outcomes, and the Mantel-Haenszel method was used to calculate the odds ratio with a 95% confidence interval. Results: Data from 2165 patients were analysed. Colchicine reduced A fib OR = 0.61 (p = 0.001), pericarditis OR = 0.54 (p = 0.07), and the need for re-ablation OR = 0.53 (p = 0.36). However, it increased GI adverse effects OR = 3.15 (p = 0.008). There was no statistical difference in the need for cardioversion, repeat hospitalisation, and atrial tachycardia between the two groups. Conclusions: Although colchicine significantly reduced the recurrence of A fib, further investigation is needed for a comprehensive understanding of the efficacy of colchicine in patients with catheter ablation.
- Open Access
- 23 May 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (6) , 222
Cardiovascular Outcomes with Colchicine in Coronary Artery Disease and HFpEF: A Propensity-Matched TriNetX Analysis
Background: Coronary artery disease (CAD) and heart failure with preserved ejection fraction (HFpEF) are major causes of morbidity and mortality. Systemic inflammation contributes to both, suggesting potential benefit from colchicine, though data in CAD-HFpEF are limited. Methods: We conducted a real-world study using the TriNetX Research Network, identifying 480,434 adults with CAD and HFpEF. Patients were categorized as colchicine users (n = 30,254) or non-users (n = 450,180). One-to-one propensity score matching yielded 28,941 patients per group. The primary outcome was a composite of acute myocardial infarction, stroke, all-cause mortality, and acute heart failure. Secondary outcomes included individual components, hospitalizations, atrial fibrillation, and gastrointestinal events, assessed at 1- and 3-year follow-up. Results: At 1 year, the primary outcome occurred in 16.9% of the colchicine group versus 19.8% of non-users (HR: 0.86, 95% CI: 0.81–0.91; p < 0.001). All-cause mortality was 11.4% versus 14.5% (HR: 0.77, 95% CI: 0.73–0.80; p < 0.001). At 3 years, the primary outcome occurred in 34.2% versus 39.7% (HR: 0.88, 95% CI: 0.85–0.92; p < 0.001), with acute heart failure slightly higher in the colchicine group (27.5% vs. 26.5%; HR: 1.04, 95% CI: 1.01–1.08; p = 0.009). Stroke was modestly reduced (HR: 0.93, 95% CI: 0.88–0.99; p = 0.014). No significant differences were seen in all-cause hospitalization, atrial fibrillation, or gastrointestinal events. Conclusions: In patients with CAD and HFpEF, colchicine was associated with lower short- and medium-term risk of composite cardiovascular events and mortality, with modest attenuation over time, suggesting early time-dependent association rather than sustained structural effects. Prospective randomized trials are warranted.
- 23 May 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (6) , 222
Open AccessCardiovascular Outcomes with Colchicine in Coronary Artery Disease and HFpEF: A Propensity-Matched TriNetX Analysis
Background: Coronary artery disease (CAD) and heart failure with preserved ejection fraction (HFpEF) are major causes of morbidity and mortality. Systemic inflammation contributes to both, suggesting potential benefit from colchicine, though data in CAD-HFpEF are limited. Methods: We conducted a real-world study using the TriNetX Research Network, identifying 480,434 adults with CAD and HFpEF. Patients were categorized as colchicine users (n = 30,254) or non-users (n = 450,180). One-to-one propensity score matching yielded 28,941 patients per group. The primary outcome was a composite of acute myocardial infarction, stroke, all-cause mortality, and acute heart failure. Secondary outcomes included individual components, hospitalizations, atrial fibrillation, and gastrointestinal events, assessed at 1- and 3-year follow-up. Results: At 1 year, the primary outcome occurred in 16.9% of the colchicine group versus 19.8% of non-users (HR: 0.86, 95% CI: 0.81–0.91; p < 0.001). All-cause mortality was 11.4% versus 14.5% (HR: 0.77, 95% CI: 0.73–0.80; p < 0.001). At 3 years, the primary outcome occurred in 34.2% versus 39.7% (HR: 0.88, 95% CI: 0.85–0.92; p < 0.001), with acute heart failure slightly higher in the colchicine group (27.5% vs. 26.5%; HR: 1.04, 95% CI: 1.01–1.08; p = 0.009). Stroke was modestly reduced (HR: 0.93, 95% CI: 0.88–0.99; p = 0.014). No significant differences were seen in all-cause hospitalization, atrial fibrillation, or gastrointestinal events. Conclusions: In patients with CAD and HFpEF, colchicine was associated with lower short- and medium-term risk of composite cardiovascular events and mortality, with modest attenuation over time, suggesting early time-dependent association rather than sustained structural effects. Prospective randomized trials are warranted.
- Open Access
- 14 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1108
Comparative Effectiveness of Finerenone Versus SGLT2 Inhibitors in Patients with HFpEF and CKD: A Real-World Propensity-Matched TriNetX Analysis
Background: Finerenone and sodium–glucose cotransporter-2 inhibitors provide cardiovascular and renal benefits in patients with chronic kidney disease (CKD) and heart failure (HF), but real-world comparative evidence is limited. Methods: This retrospective study used the TriNetX database. Adults ≥ 40 years with CKD stages 1–5 and HF [LVEF > 40%; excluding end-stage renal disease (ESRD) or dialysis] receiving finerenone were compared with those on SGLT2 inhibitors. Propensity score matching (1:1) yielded 333 patients per cohort. Kaplan–Meier and Cox models estimated hazard ratios (HRs) with 95% confidence intervals. Results: After matching, baseline characteristics were reasonably balanced, with some residual imbalance remaining. All-cause mortality was similar between finerenone and SGLT2 inhibitors at 6 months (HR 0.98; 95% CI 0.50–1.90) and 1 year (HR 0.93; 95% CI 0.53–1.66). All-cause hospitalization or ER visits were also comparable at 6 months (HR 1.07; 95% CI 0.84–1.36) and 1 year (HR 1.04; 95% CI 0.83–1.29). Finerenone was associated with a modest, borderline reduction in HF hospitalization at 1 year, without consistent effects across timepoints or a mortality benefit; thus, this finding is hypothesis-generating (HR 0.81; 95% CI 0.66–0.99). Safety outcomes were similar between groups. Conclusions: In this real-world analysis, finerenone was associated with similar all-cause mortality, overall hospitalization, and renal safety outcomes compared with SGLT2 inhibitors, with a modest reduction in HF hospitalization at 1 year that should be interpreted cautiously given the exploratory nature of the study. These findings are hypothesis-generating and underscore the need for prospective head-to-head trials to better define optimal therapy sequencing in patients with HFpEF and CKD.
- 14 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1108
Open AccessComparative Effectiveness of Finerenone Versus SGLT2 Inhibitors in Patients with HFpEF and CKD: A Real-World Propensity-Matched TriNetX Analysis
Background: Finerenone and sodium–glucose cotransporter-2 inhibitors provide cardiovascular and renal benefits in patients with chronic kidney disease (CKD) and heart failure (HF), but real-world comparative evidence is limited. Methods: This retrospective study used the TriNetX database. Adults ≥ 40 years with CKD stages 1–5 and HF [LVEF > 40%; excluding end-stage renal disease (ESRD) or dialysis] receiving finerenone were compared with those on SGLT2 inhibitors. Propensity score matching (1:1) yielded 333 patients per cohort. Kaplan–Meier and Cox models estimated hazard ratios (HRs) with 95% confidence intervals. Results: After matching, baseline characteristics were reasonably balanced, with some residual imbalance remaining. All-cause mortality was similar between finerenone and SGLT2 inhibitors at 6 months (HR 0.98; 95% CI 0.50–1.90) and 1 year (HR 0.93; 95% CI 0.53–1.66). All-cause hospitalization or ER visits were also comparable at 6 months (HR 1.07; 95% CI 0.84–1.36) and 1 year (HR 1.04; 95% CI 0.83–1.29). Finerenone was associated with a modest, borderline reduction in HF hospitalization at 1 year, without consistent effects across timepoints or a mortality benefit; thus, this finding is hypothesis-generating (HR 0.81; 95% CI 0.66–0.99). Safety outcomes were similar between groups. Conclusions: In this real-world analysis, finerenone was associated with similar all-cause mortality, overall hospitalization, and renal safety outcomes compared with SGLT2 inhibitors, with a modest reduction in HF hospitalization at 1 year that should be interpreted cautiously given the exploratory nature of the study. These findings are hypothesis-generating and underscore the need for prospective head-to-head trials to better define optimal therapy sequencing in patients with HFpEF and CKD.
- 17 April 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (6) , 1-14
Optical coherence tomography versus angiography guided percutaneous coronary intervention: a systematic review and meta-analysis
- 17 April 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (6) , 1-14
Optical coherence tomography versus angiography guided percutaneous coronary intervention: a systematic review and meta-analysis
- 5 April 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (7) , 2275-2286
Cardiovascular Outcomes of Drug‐Coated Balloon Versus Drug‐Eluting Stents for Femoropopliteal Peripheral Arterial Disease Interventions: A Meta‐Regression Analysis
Background: Outcomes comparing drug‐coated balloons (DCB) versus drug‐eluting stents (DES) have not been sufficiently studied in femoropopliteal peripheral arterial disease (PAD). Aims: This meta‐analysis aims to compare outcomes of DES versus DCBs in femoropopliteal PAD and uses regression to rule out effect modifiers. Methods: An online literature search was conducted using the Preferred Reporting Items for Systematic Review and Meta‐Analysis search strategy from inception till November 2022. STATA v.17 was used for statistical analysis to calculate odds ratios and for univariate meta‐regression to rule out effect modifiers, including baseline characteristics and comorbidities. Results: A total of eight studies with 1261 patients underwent femoropopliteal peripheral arterial intervention (DCB, n = 670; DES, n = 591). There was no difference in the primary outcome of all‐cause mortality and primary patency at 1 year and 2 years between DCB and DES. One‐year clinically‐driven target lesion revascularization (CD‐TLR) was significantly lower in the DCB group (OR: 0.68; 95% CI = 0.47–0.98; p = 0.04); however, no significant difference was found in 2‐year CD‐TLR. Regarding secondary outcomes' analysis, major amputation, procedural success, and post‐procedure ankle‐brachial index (ABI) failed to reach statistical significance. Univariate meta‐regression results showed no effect modification based on demographics, comorbidities, and lesion characteristics ( p > 0.05) for all outcomes except 1‐year CD‐TLR and major amputation. Conclusion: There was no significant difference in all‐cause mortality and primary patency between DCB and DES for up to 2 years. DCB was associated with lower CD‐TLR at 1 year, which was lost at 2 years of follow‐up.
- 5 April 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (7) , 2275-2286
Cardiovascular Outcomes of Drug‐Coated Balloon Versus Drug‐Eluting Stents for Femoropopliteal Peripheral Arterial Disease Interventions: A Meta‐Regression Analysis
Background: Outcomes comparing drug‐coated balloons (DCB) versus drug‐eluting stents (DES) have not been sufficiently studied in femoropopliteal peripheral arterial disease (PAD). Aims: This meta‐analysis aims to compare outcomes of DES versus DCBs in femoropopliteal PAD and uses regression to rule out effect modifiers. Methods: An online literature search was conducted using the Preferred Reporting Items for Systematic Review and Meta‐Analysis search strategy from inception till November 2022. STATA v.17 was used for statistical analysis to calculate odds ratios and for univariate meta‐regression to rule out effect modifiers, including baseline characteristics and comorbidities. Results: A total of eight studies with 1261 patients underwent femoropopliteal peripheral arterial intervention (DCB, n = 670; DES, n = 591). There was no difference in the primary outcome of all‐cause mortality and primary patency at 1 year and 2 years between DCB and DES. One‐year clinically‐driven target lesion revascularization (CD‐TLR) was significantly lower in the DCB group (OR: 0.68; 95% CI = 0.47–0.98; p = 0.04); however, no significant difference was found in 2‐year CD‐TLR. Regarding secondary outcomes' analysis, major amputation, procedural success, and post‐procedure ankle‐brachial index (ABI) failed to reach statistical significance. Univariate meta‐regression results showed no effect modification based on demographics, comorbidities, and lesion characteristics ( p > 0.05) for all outcomes except 1‐year CD‐TLR and major amputation. Conclusion: There was no significant difference in all‐cause mortality and primary patency between DCB and DES for up to 2 years. DCB was associated with lower CD‐TLR at 1 year, which was lost at 2 years of follow‐up.
- 30 January 2026
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
Impella in Cardiogenic Shock: An Updated Meta-Analysis
Despite technological advancements, mortality remains high in patients with myocardial infarction complicated by cardiogenic shock. Impella is increasingly used as an adjunct to standard treatment due to its hemodynamic benefits, though mixed study results limit its adoption. This meta-analysis aims to clarify Impella’s efficacy by focusing on high-quality data from RCTs and cohort studies. A comprehensive literature search was conducted for randomized controlled trials and cohort studies comparing Impella with intra-aortic balloon pump (IABP) and extracorporeal membrane oxygenation (ECMO). Assessed metrics included mortality, clinical events, and hematologic markers. Data was analyzed using the Mantel-Haenszel random-effects model. Of 787 articles, 12 studies (4918 patients) met the inclusion criteria. Impella groups showed significant increases in thrombosis risk (RR: 4.94) and had a higher bleeding risk compared to IABP (RR: 1.98) but a lower risk compared to ECMO (RR: 0.66). All other comparisons did not reach statistical significance. Despite updated data and a stringent quality threshold, the hemodynamic benefits of Impella and the device’s risk of thrombosis and bleeding were high. Future trials should emphasize patient selection, timing of placement, and operator proficiency to evaluate Impella’s efficacy and safety better.
- 30 January 2026
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
Impella in Cardiogenic Shock: An Updated Meta-Analysis
Despite technological advancements, mortality remains high in patients with myocardial infarction complicated by cardiogenic shock. Impella is increasingly used as an adjunct to standard treatment due to its hemodynamic benefits, though mixed study results limit its adoption. This meta-analysis aims to clarify Impella’s efficacy by focusing on high-quality data from RCTs and cohort studies. A comprehensive literature search was conducted for randomized controlled trials and cohort studies comparing Impella with intra-aortic balloon pump (IABP) and extracorporeal membrane oxygenation (ECMO). Assessed metrics included mortality, clinical events, and hematologic markers. Data was analyzed using the Mantel-Haenszel random-effects model. Of 787 articles, 12 studies (4918 patients) met the inclusion criteria. Impella groups showed significant increases in thrombosis risk (RR: 4.94) and had a higher bleeding risk compared to IABP (RR: 1.98) but a lower risk compared to ECMO (RR: 0.66). All other comparisons did not reach statistical significance. Despite updated data and a stringent quality threshold, the hemodynamic benefits of Impella and the device’s risk of thrombosis and bleeding were high. Future trials should emphasize patient selection, timing of placement, and operator proficiency to evaluate Impella’s efficacy and safety better.
- 22 January 2026
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 371 (5) , 434-440
Transcatheter aortic valve replacement for mixed aortic valve disease: An updated meta-analysis and systematic review
- 22 January 2026
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 371 (5) , 434-440
Transcatheter aortic valve replacement for mixed aortic valve disease: An updated meta-analysis and systematic review
- Open Access
- 11 December 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (1)
Surgical Left Atrial Appendage Occlusion During Cardiac Surgery in Atrial Fibrillation: A Contemporary Systematic Review and Meta-Analysis
- 11 December 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (1)
Open AccessSurgical Left Atrial Appendage Occlusion During Cardiac Surgery in Atrial Fibrillation: A Contemporary Systematic Review and Meta-Analysis